Page last updated: 2024-08-21

quinazolines and hydroxyurea

quinazolines has been researched along with hydroxyurea in 116 studies

Research

Studies (116)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	7 (6.03)	18.2507
2000's	62 (53.45)	29.6817
2010's	39 (33.62)	24.3611
2020's	8 (6.90)	2.80

Authors

Authors	Studies
Frenkel, EP	1
Mughal, TI	1
Barbui, T; Brière, J; Dupuy, E; Finazzi, G; Kiladjian, JJ	1
Chernoff, SG; Ruiz-Argüelles, GJ; Ruiz-Delgado, GJ; Ruiz-Reyes, G	1
Silverstein, MN; Tefferi, A	1
Barbui, T; Finazzi, G; Fuchtman, SM; Kutti, J; Michiels, JJ; Rain, JD; Silver, RT; Tefferi, A; Thiele, J	1
Green, AR	1
Hehlmann, R; Lengfelder, E	1
Pavithran, K; Somarajan, A; Thomas, M	1
Cervantes, F	2
Briere, J; Guilmin, F	1
Bangerter, M; Griesshammer, M; Grünewald, M	1
Tefferi, A; Wright, CA	1
Bennett, M; Grunwald, AJ	1
Ikeda, Y	1
Gilbert, HS	3
Eftyhiadis, E; Komninaka, V; Loukopoulos, D; Mantzourani, M; Terpos, E; Voskaridou, E	1
Solberg, LA	1
Adams, J; Bennett, CL; Dave, S; Golub, R	1
Giles, FJ; Tsimberidou, AM	1
Erusalimsky, JD; Hong, Y	1
Barbui, T	2
Barbui, T; Finazzi, G; Rodeghiero, F; Ruggeri, M	1
Brink, DJ; Mazer, MA; Raghavan, M	1
Griesshammer, M; Langer, C	1
Castañón, M; Correa, G; Genoud, V; Heller, PG; Kordich, L; Kornblihtt, LI; Molinas, FC; Sarano, J; Vassallu, P	1
Schafer, AI	1
Cheung, MC; Hicks, LK; Pendergrast, J	1
Campbell, PJ; Curtin, N; Green, AR; Vassiliou, GS	1
Fruchtman, SM	1
Petrides, PE	3
Silver, RT	1
Dame, C; Sutor, AH	1
Bareford, D; Buck, G; Campbell, PJ; East, CL; Green, AR; Grigg, AP; Harrison, CN; Reilly, JT; Revell, P; van der Walt, JD; Wheatley, K; Wilkins, BS; Woodcock, BE	1
Barbui, T; Finazzi, G	2
Dingli, D; Tefferi, A	1
Costello, R; O'Callaghan, T; Sébahoun, G	1
Kvasnicka, HM; Ollig, S; Schmitt-Gräff, A; Thiele, J	1
Fruchtman, S	1
Del Arroyo, AG; Erusalimsky, JD; Hernandez, J; Hong, Y; Skene, C; Wang, G	1
Harrison, CN	1
Cabello, P; Cesar, JM; Ferro, T; Navarro, JL	1
Kvasnicka, HM; Schmitt-Graeff, A; Thiele, J	1
Giles, F; Kantarjian, HM; Quintás-Cardama, A; Verstovsek, S	1
Gisslinger, H	1
Lee, LH; Wong, GC	1
Chang, H; Cheong, JW; Choi, D; Jang, Y; Ko, YG; Pyo, JY; Shim, CY	1
Dissemond, J; Grabbe, S; Körber, A; Rappoport, L	1
Birgegård, G	2
Griesshammer, M	1
Reilly, JT	1
Bareford, D; Buck, G; Campbell, PJ; East, CL; Erber, WN; Green, AR; Harrison, CN; Paul, B; Wheatley, K; Wilkins, BS	1
Cacciola, E; Cacciola, RR; Di Francesco, E; Giustolisi, R; Pezzella, F; Tibullo, D	1
D'adda, M; Drera, M; Ferrari, S; Micheletti, M; Rossi, G	1
Anastasiadis, A; Bourikas, G; Christoforidou, A; Goutzouvelidis, A; Kaloutsi, V; Kotsianidis, I; Margaritis, D; Pantelidou, D; Spanoudakis, E; Tsatalas, C	1
de Stricker, K; Hasselbalch, HC; Larsen, TS; Møller, MB; Pallisgaard, N	1
Bareford, D; Buck, G; Campbell, PJ; Erber, WN; Green, AR; Harrison, CN; Wheatley, K; Wilkins, BS; Wright, P	1
Beer, PA; Green, AR	1
Demulder, AC; Malarme, M; Mesquita, Mdo C; Noubouossie, D; Sol, EB	1
How, CK; Huang, MS; Su, PH; Yen, DH	1
Finazzi, G	1
Cebula-Obrzut, B; Chojnowski, K; Smolewski, P; Treliński, J	1
Dowson, A; Frewin, R	1
Besses, C; Birgegård, G; Coll, R; Griesshammer, M; Gugliotta, L; Harrison, C; Kiladjian, JJ; Smith, J	1
Gisslinger, H; Gotic, M; Holowiecki, J; Kralovics, R; Kvasnicka, HM; Penka, M; Petrides, PE; Thiele, J	1
Alvarez-Larrán, A; Antelo, ML; Arellano-Rodrigo, E; Besses, C; Cervantes, F; Ferrer-Marín, F; Gómez, M; Hernández-Boluda, JC; Kerguelen, A; Márquez, JA; Pereira, A	1
Alvarez-Larrán, A; Besses, C; Cervantes, F	1
Haznedaroglu, IC	1
Fu, R; Yang, R; Zhang, L	1
Ahn, IE; Natelson, E; Rice, L	1
Chaudhary, R; Nityanand, S; Singh, A	1
Abhyankar, B; Besses, C; Birgegård, G; Coll, R; Griesshammer, M; Gugliotta, L; Harrison, C; Kiladjian, JJ; Smith, J	1
Newberry, KJ; Sever, M; Verstovsek, S	1
Ballester-Sánchez, R; de Unamuno-Bustos, B; Sabater Marco, V; Vilata-Corell, JJ	1
Böhmer, FD; Kirches, E; Mawrin, C; Pachow, D; Petermann, A; Wallesch, M; Wilisch-Neumann, A	1
De Raeve, H; Gadisseur, A; Michiels, JJ; Pich, A	1
Miyamoto, T; Yoshimoto, G	1
Bergmann, F; Griesshammer, M; Koschmieder, S; Kreher, S; Matzdorff, A; Ochsenreither, S; Pabinger, I; Petrides, PE; Riess, H; Tiede, A; Trappe, RU	1
Double, G; Harrison, C	1
Bang, SM; Kim, JW; Kim, SH; Kim, YJ; Lee, JO; Lee, JS; Lee, KW; Lim, Y	1
Hoffman, R; Kremyanskaya, M; Mascarenhas, J	1
Chai-Adisaksopha, C; Garcia, D; Samuelson, B	1
Cao, X; Fu, J; Gao, D; Ge, X; Hou, M; Jiang, B; Jin, J; Li, J; Li, K; Qian, W; Su, L; Sun, A; Wang, S; Wang, Z; Xiao, Z; Yang, L; Yang, R; Zhang, W; Zhang, X; Zhao, Y	1
Aksu, S; Büyükaşık, Y; Eliaçık, E; Göker, H; Haznedaroğlu, İC; Işık, A; Özcebe, OI; Sayınalp, N; Üner, A	1
Burlando, M; Cattaneo, D; Cozzani, E; Gugliotta, L; Iurlo, A; Merlo, G; Parodi, A; Pierri, I	1
Iványi, JL; Marton, É; Plander, M; Szendrei, T	1
Besses, C; Burgaleta, C; Hernández-Boluda, JC; Hernández-Rivas, JM; Jiménez Velasco, A; Martínez Lopez, J; Pérez Encinas, M; Raya, JM; Vicente, V	1
Akay, OM; Andıç, N; Bolaman, AZ; Kadıköylü, VG; Ünübol, M; Yağcı, E; Yavaşoğlu, İ	1
Fujimura, K; Shimazu, Y	1
Demeter, J; Dombi, P; Egyed, M; Homor, L; Illés, Á; Karadi, E; Simon, Z; Udvardy, M	1
Corvetta, D; Di Pierro, AM; Eakins, E; Feistritzer, C; Gambato, R; Gastl, G; Gherlinzoni, F; Gottardi, M; Krampera, M; Langes, M; Marcheselli, L; Mazzoleni, G; Mega, A; Murphy, C; Pacquola, E; Perbellini, O; Piccin, A; Piva, E; Plebani, M; Pusceddu, I; Steurer, M; Tauber, M; Van Schilfgaarde, M; Veneri, D	1
Baek, S; Choi, SY; Lee, H; Na, J	1
Alimena, G; Anaclerico, B; Andriani, A; Avvisati, G; Baldacci, E; Breccia, M; Buccisano, F; Cedrone, M; Cimino, G; De Gregoris, C; De Muro, M; Di Veroli, A; Latagliata, R; Leonetti Crescenzi, S; Mazzucconi, MG; Montanaro, M; Montefusco, E; Porrini, R; Rago, A; Santoro, C; Spadea, A; Sperduti, I; Spirito, F; Villivà, N	1
Usui, N	1
Greenspan, A; Lu, M; Rodriguez-Ziccardi, M; Rubio, M	1
Hwang, JH; Kim, DW; Kim, KS; Lee, SY	1
Achenbach, H; Besses, C; Birgegård, G; Folkvaljon, F; Garmo, H; Griesshammer, M; Gugliotta, L; Harrison, CN; Holmberg, L; Kiladjian, JJ; Wu, J	1
Fukuda, Y; Hamano, Y; Iizuka, H; Inano, T; Izumi, H; Nakamura, N; Noguchi, M; Okubo, M; Sakajiri, S; Sawada, T; Sekiguchi, Y; Sugimoto, K; Takizawa, H; Tomita, S; Wakabayashi, M	1
Besses, C; Blau, IW; Dong, T; Durrant, S; Francillard, N; Griesshammer, M; Harrison, CN; Hino, M; Kiladjian, JJ; Kirito, K; Masszi, T; Mesa, R; Miller, CB; Moiraghi, B; Pane, F; Passamonti, F; Rosti, V; Rumi, E; Vannucchi, AM; Verstovsek, S; Wroclawska, M; Zachee, P	1
Demeter, J; Dombi, P; Egyed, M; Ercsei, I; Gasztonyi, Z; Gy Korom, V; Herczeg, J; Homor, L; Illes, A; Karadi, E; Kellner, A; Simon, Z; Szerafin, L; Udvardy, M	1
Alvarez-Larrán, A; Andrade-Campos, M; Angona, A; Bellosillo, B; Caballero, G; Carreño-Tarragona, G; Cuevas, B; Ferrer-Marín, F; Fox, L; García-Gutiérrez, V; García-Hernández, C; Guerrero, L; Hernández-Boluda, JC; Isabel Mata-Vázquez, M; Magro, E; Manuel Alonso-Domínguez, J; María Guerra, J; María Raya, J; Moretó, A; Murillo, I; Palomino, A; Pastor-Galán, I; Pérez-Encinas, M; Soledad Noya, M; Teresa Gómez-Casares, M	1
Achenbach, H; Egyed, M; Gercheva, L; Gotic, M; Kvasnicka, HM; Warzocha, K; Wu, J	1
Jaźwiec, B; Kuliszkiewicz-Janus, M; Kwiatkowski, J; Małecki, R; Rymer, W	1
Cario, H; Duffert, CM; Knöfler, R; Kulozik, AE; Stockklausner, C; Streif, W	1
Krečak, I; Lucijanić, M	1
Gill, H; Hou, HA; Jin, J; Komatsu, N; Lee, SE; Mesa, RA; Qin, A; Sato, T; Shih, W; Urbanski, R; Verstovsek, S; Zagrijtschuk, O; Zimmerman, C	1

Reviews

48 review(s) available for quinazolines and hydroxyurea

Article	Year
The clinical spectrum of thrombocytosis and thrombocythemia. The American journal of the medical sciences, 1991, Volume: 301, Issue:1 Topics: Blood Platelets; Cytokines; Hematopoiesis; Humans; Hydroxyurea; Interferon Type I; Megakaryocytes; Platelet Aggregation; Platelet Count; Quinazolines; Thrombocythemia, Essential; Thrombocytosis	1991
Primary thrombocythemia: a current perspective. Stem cells (Dayton, Ohio), 1995, Volume: 13, Issue:4 Topics: Aspirin; Diagnosis, Differential; Humans; Hydroxyurea; Interferon Type I; Myeloproliferative Disorders; Platelet Aggregation Inhibitors; Plateletpheresis; Quinazolines; Recombinant Proteins; Thrombocytosis	1995
Treatment strategies in essential thrombocythemia. A critical appraisal of various experiences in different centers. Leukemia & lymphoma, 1996, Volume: 22 Suppl 1 Topics: Adult; Aged; Alkylating Agents; Anemia, Megaloblastic; Arrhythmias, Cardiac; Bone Marrow Diseases; Busulfan; Female; Hemorrhage; Humans; Hydroxyurea; Immunologic Factors; Incidence; Interferon-alpha; Ischemic Attack, Transient; Leukemia; Male; Middle Aged; Pipobroman; Platelet Aggregation Inhibitors; Platelet Count; Prognosis; Quinazolines; Risk Factors; Thrombocythemia, Essential; Thrombosis	1996
Treatment of polycythaemia vera and essential thrombocythaemia. Bailliere's clinical haematology, 1998, Volume: 11, Issue:4 Topics: Adult; Aged; Aspirin; Chlorambucil; Disease Progression; Female; Hemorrhage; Humans; Hydroxyurea; Interferon-alpha; Leukemia, Myeloid; Leukemia, Radiation-Induced; Male; Middle Aged; Phlebotomy; Phosphorus Radioisotopes; Pipobroman; Polycythemia Vera; Primary Myelofibrosis; Prospective Studies; Quinazolines; Thrombocythemia, Essential; Thrombosis	1998
Diagnosis and treatment of polycythemia vera and possible future study designs of the PVSG. Leukemia & lymphoma, 2000, Volume: 36, Issue:3-4 Topics: Blood Platelets; Forecasting; Humans; Hydroxyurea; Interferon-alpha; Megakaryocytes; Platelet Aggregation Inhibitors; Polycythemia Vera; Prospective Studies; Quinazolines; Randomized Controlled Trials as Topic	2000
The pathogenesis and management of essential thrombocythaemia. Haematologica, 1999, Volume: 84 Suppl EHA-4 Topics: Acute Disease; Alkylating Agents; Aspirin; Cardiovascular Diseases; Clone Cells; Gene Expression; Hemorrhage; Humans; Hydroxyurea; Leukemia, Myeloid; Megakaryocytes; Platelet Aggregation Inhibitors; Quinazolines; Risk; Thrombocythemia, Essential; Thrombophilia	1999
[Polycythemia vera: current status of therapy]. Deutsche medizinische Wochenschrift (1946), 2000, Oct-13, Volume: 125, Issue:41 Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Bloodletting; Clinical Trials as Topic; Fibrinolytic Agents; Humans; Hydroxyurea; Interferon-alpha; Leukemia; Middle Aged; Phlebotomy; Pipobroman; Platelet Aggregation Inhibitors; Polycythemia Vera; Prognosis; Prospective Studies; Quinazolines; Randomized Controlled Trials as Topic; Retrospective Studies; Risk Factors; Thromboembolism	2000
Prognostic factors and current practice in treatment of myelofibrosis with myeloid metaplasia: an update anno 2000. Pathologie-biologie, 2001, Volume: 49, Issue:2 Topics: Aged; Anemia; Aneuploidy; Angiogenesis Inhibitors; Bone Marrow Transplantation; Case Management; Combined Modality Therapy; Female; Hemoglobins; Humans; Hydroxyurea; Karyotyping; Male; Middle Aged; Palliative Care; Primary Myelofibrosis; Prognosis; Quinazolines; Risk; Severity of Illness Index; Splenectomy; Survival Analysis; Thalidomide	2001
Management of patients with essential thrombocythemia: current concepts and perspectives. Pathologie-biologie, 2001, Volume: 49, Issue:2 Topics: Adult; Aged; Aspirin; Case Management; Clinical Trials as Topic; Diagnosis, Differential; Disease Progression; Female; Hemorrhagic Disorders; Humans; Hydroxyurea; Interferons; Leukemia; Male; Middle Aged; Pipobroman; Platelet Aggregation Inhibitors; Platelet Count; Pregnancy; Pregnancy Complications, Hematologic; Prospective Studies; Quinazolines; Risk; Safety; Thrombocythemia, Essential; Thrombophilia	2001
Current treatment practice for essential thrombocythaemia in adults. Expert opinion on pharmacotherapy, 2001, Volume: 2, Issue:3 Topics: Adult; Aspirin; Humans; Hydroxyurea; Interferon-alpha; Pipobroman; Prognosis; Quinazolines; Thrombocythemia, Essential	2001
A single institutional experience with 43 pregnancies in essential thrombocythemia. European journal of haematology, 2001, Volume: 66, Issue:3 Topics: Abortion, Induced; Abortion, Spontaneous; Abruptio Placentae; Adult; Anticoagulants; Aspirin; Busulfan; Erythromelalgia; Female; Fetal Death; Follow-Up Studies; Heparin; Humans; Hydroxyurea; Migraine Disorders; Obstetric Labor, Premature; Phosphorus Radioisotopes; Platelet Aggregation Inhibitors; Platelet Count; Plateletpheresis; Pregnancy; Pregnancy Complications, Hematologic; Pregnancy Outcome; Pregnancy Trimester, First; Pregnancy, Ectopic; Pregnancy, High-Risk; Quinazolines; Retrospective Studies; Risk; Thrombocythemia, Essential; Uterine Hemorrhage	2001
Diagnosis and treatment of thrombocythemia in myeloproliferative disorders. Oncology (Williston Park, N.Y.), 2001, Volume: 15, Issue:8 Topics: Enzyme Inhibitors; Humans; Hydroxyurea; Immunologic Factors; Interferon-alpha; Polycythemia Vera; Quinazolines; Thrombocytosis	2001
Therapeutic options for essential thrombocythemia and polycythemia vera. Seminars in oncology, 2002, Volume: 29, Issue:3 Suppl 10 Topics: Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Aspirin; Busulfan; Fibrinolytic Agents; Humans; Hydroxyurea; Immunologic Factors; Immunosuppressive Agents; Interferon-alpha; Nucleic Acid Synthesis Inhibitors; Phosphorus Radioisotopes; Polycythemia Vera; Quinazolines; Risk Assessment; Thrombocytosis	2002
Other secondary sequelae of treatments for myeloproliferative disorders. Seminars in oncology, 2002, Volume: 29, Issue:3 Suppl 10 Topics: Antineoplastic Agents; Fibrinolytic Agents; Humans; Hydroxyurea; Immunologic Factors; Interferon-alpha; Nucleic Acid Synthesis Inhibitors; Polycythemia; Quinazolines; Thrombocytosis	2002
Essential thrombocythemia (ET): moving from palliation to cure. Hematology (Amsterdam, Netherlands), 2002, Volume: 7, Issue:6 Topics: Female; Humans; Hydroxyurea; Interferon alpha-2; Interferon-alpha; Male; Palliative Care; Pregnancy; Pregnancy Complications, Hematologic; Quinazolines; Recombinant Proteins; Thrombocythemia, Essential	2002
Comparison of the pharmacological mechanisms involved in the platelet lowering actions of anagrelide and hydroxyurea: a review. Platelets, 2002, Volume: 13, Issue:7 Topics: Blood Platelets; Humans; Hydroxyurea; Platelet Aggregation Inhibitors; Quinazolines; Risk Assessment; Thrombocytosis	2002
Indications for lowering platelet numbers in essential thrombocythemia. Seminars in hematology, 2003, Volume: 40, Issue:1 Suppl 1 Topics: Age Factors; Drug Therapy, Combination; Humans; Hydroxyurea; Interferon-alpha; Platelet Aggregation Inhibitors; Platelet Count; Quinazolines; Risk Factors; Thrombocythemia, Essential; Thrombosis	2003
Modern treatment strategies in polycythemia vera. Seminars in hematology, 2003, Volume: 40, Issue:1 Suppl 1 Topics: Age Factors; Antineoplastic Agents; Drug Therapy, Combination; Humans; Hydroxyurea; Interferon-alpha; Phlebotomy; Platelet Aggregation Inhibitors; Polycythemia Vera; Quinazolines; Risk Factors	2003
Pharmacotherapy of essential thrombocythaemia: economic considerations. Expert opinion on pharmacotherapy, 2003, Volume: 4, Issue:9 Topics: Age Factors; Antineoplastic Agents; Aspirin; Clinical Trials, Phase II as Topic; Cost-Benefit Analysis; Humans; Hydroxyurea; Interferon-alpha; Pipobroman; Quinazolines; Risk Factors; Thrombocythemia, Essential	2003
Thrombocytosis. The New England journal of medicine, 2004, Mar-18, Volume: 350, Issue:12 Topics: Aspirin; Clone Cells; Diagnosis, Differential; Humans; Hydroxyurea; Interferon-alpha; Plasmapheresis; Platelet Aggregation Inhibitors; Quinazolines; Thrombocythemia, Essential; Thrombocytosis	2004
Management of the myeloproliferative disorders : distinguishing data from dogma. The hematology journal : the official journal of the European Haematology Association, 2004, Volume: 5 Suppl 3 Topics: Abnormalities, Drug-Induced; Adult; Aged; Anticoagulants; Contraindications; Female; Humans; Hydroxyurea; Interferon-alpha; Male; Middle Aged; Myeloproliferative Disorders; Phlebotomy; Polycythemia Vera; Pregnancy; Pregnancy Complications, Hematologic; Prognosis; Quinazolines; Randomized Controlled Trials as Topic; Thrombocythemia, Essential; Thrombophilia	2004
The leukemia controversy in myeloproliferative disorders: is it a natural progression of disease, a secondary sequela of therapy, or a combination of both? Seminars in hematology, 2004, Volume: 41, Issue:2 Suppl 3 Topics: Age Factors; Aged; Antineoplastic Agents, Alkylating; Antiviral Agents; Disease Progression; Female; Humans; Hydroxyurea; Interferon-alpha; Leukemia; Male; Middle Aged; Platelet Aggregation Inhibitors; Polycythemia Vera; Quinazolines; Risk Factors; Thrombocythemia, Essential; Thrombosis	2004
Treatment paradigms in the management of myeloproliferative disorders. Seminars in hematology, 2004, Volume: 41, Issue:2 Suppl 3 Topics: Antineoplastic Agents, Alkylating; Busulfan; Chlorambucil; Hydroxyurea; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Myelodysplastic Syndromes; Myeloproliferative Disorders; Philadelphia Chromosome; Platelet Aggregation Inhibitors; Quinazolines; Radiopharmaceuticals	2004
Anagrelide: a decade of clinical experience with its use for the treatment of primary thrombocythaemia. Expert opinion on pharmacotherapy, 2004, Volume: 5, Issue:8 Topics: Animals; Carcinogens; Clinical Trials as Topic; Drug Therapy, Combination; Heart Diseases; Humans; Hydroxyurea; Interferon Type I; Mutagens; Platelet Aggregation Inhibitors; Platelet Count; Quinazolines; Recombinant Proteins; Thrombocythemia, Essential; Thromboembolism	2004
Primary and secondary thrombocytosis in childhood. British journal of haematology, 2005, Volume: 129, Issue:2 Topics: Adolescent; Bacterial Infections; Blood Platelets; Child; Child, Preschool; Humans; Hydroxyurea; Infant; Infant, Newborn; Liver; Megakaryocytes; Mutation; Nucleic Acid Synthesis Inhibitors; Platelet Aggregation Inhibitors; Platelet Count; Quinazolines; Thrombocytosis; Thrombopoiesis; Thrombopoietin; Virus Diseases	2005
A critical review of anagrelide therapy in essential thrombocythemia and related disorders. Leukemia & lymphoma, 2005, Volume: 46, Issue:5 Topics: Clinical Trials as Topic; Humans; Hydroxyurea; Quinazolines; Thrombocythemia, Essential; Thrombocytosis	2005
[Treatment of essential thrombocythemia]. La Revue de medecine interne, 2005, Volume: 26, Issue:12 Topics: Aspirin; Enzyme Inhibitors; Hemorrhage; Humans; Hydroxyurea; Immunologic Factors; Interferon-alpha; Platelet Aggregation Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Risk Factors; Thrombocythemia, Essential	2005
Management of essential thrombocythemia: implications of the medical research council primary thrombocythemia 1 trial. Seminars in thrombosis and hemostasis, 2006, Volume: 32, Issue:3 Topics: Disease Management; Humans; Hydroxyurea; Quinazolines; Randomized Controlled Trials as Topic; Thrombocythemia, Essential; Treatment Outcome	2006
Anagrelide: what was new in 2004 and 2005? Seminars in thrombosis and hemostasis, 2006, Volume: 32, Issue:4 Pt 2 Topics: Antineoplastic Agents; Aspirin; Blood Platelets; Clinical Trials, Phase III as Topic; Drug Therapy, Combination; Female; Fibrinolytic Agents; Hemorrhage; History, 21st Century; Humans; Hydroxyurea; Male; Megakaryocytes; Platelet Aggregation Inhibitors; Pregnancy; Pregnancy Complications, Hematologic; Quinazolines; Randomized Controlled Trials as Topic; Signal Transduction; Thrombocythemia, Essential	2006
Pegylated interferon therapy for patients with Philadelphia chromosome-negative myeloproliferative disorders. Seminars in thrombosis and hemostasis, 2006, Volume: 32, Issue:4 Pt 2 Topics: Antineoplastic Agents; Humans; Hydroxyurea; Interferon-alpha; Leukemia, Myeloid; Myeloproliferative Disorders; Philadelphia Chromosome; Quinazolines	2006
Update on diagnosis and management of essential thrombocythemia. Seminars in thrombosis and hemostasis, 2006, Volume: 32, Issue:4 Pt 2 Topics: Age Factors; Antineoplastic Agents; Aspirin; Drug Antagonism; Female; Fibrinolytic Agents; Hemorrhage; Humans; Hydroxyurea; Interferon-alpha; Life Expectancy; Male; Quinazolines; Risk Factors; Thrombocythemia, Essential	2006
[Primary thrombocythemia: diagnosis and therapy]. Medizinische Klinik (Munich, Germany : 1983), 2006, Aug-15, Volume: 101, Issue:8 Topics: Adult; Aged; Aspirin; Child; Diagnosis, Differential; Drug Therapy, Combination; Enzyme Inhibitors; Female; Follow-Up Studies; Humans; Hydroxyurea; Immunologic Factors; Interferon-alpha; Male; Mutation; Platelet Aggregation Inhibitors; Platelet Count; Pregnancy; Pregnancy Complications, Hematologic; Primary Prevention; Prospective Studies; Quinazolines; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Thrombocythemia, Essential; Time Factors	2006
Myelofibrosis: biology and treatment options. European journal of haematology. Supplementum, 2007, Issue:68 Topics: Benzamides; Chronic Disease; Darbepoetin alfa; Erythropoietin; Hematopoietic Stem Cell Transplantation; Humans; Hydroxyurea; Imatinib Mesylate; Interferon-alpha; Piperazines; Primary Myelofibrosis; Protein-Tyrosine Kinases; Pyrimidines; Quinazolines; Recombinant Proteins; Splenectomy; Thalidomide	2007
Evidence and expertise in the management of polycythemia vera and essential thrombocythemia. Leukemia, 2008, Volume: 22, Issue:8 Topics: Aspirin; Humans; Hydroxyurea; Interferon-alpha; Janus Kinase 2; Mutation; Phlebotomy; Polycythemia Vera; Quinazolines; Risk Factors; Survival Analysis; Thrombocythemia, Essential	2008
Long-term management of thrombocytosis in essential thrombocythaemia. Annals of hematology, 2009, Volume: 88, Issue:1 Topics: Algorithms; Antineoplastic Agents; Aspirin; Female; Fibrinolytic Agents; Humans; Hydroxyurea; Interferon-alpha; Janus Kinase 2; Pregnancy; PubMed; Quinazolines; Randomized Controlled Trials as Topic; Thrombocythemia, Essential; Thrombocytosis	2009
Pathogenesis and management of essential thrombocythemia. Hematology. American Society of Hematology. Education Program, 2009 Topics: Acute Disease; Aged; Aspirin; Clone Cells; Disease Management; Disease Progression; Humans; Hydroxyurea; Interferon-alpha; Janus Kinase 2; Leukemia, Myeloid; Middle Aged; Models, Biological; Mutation, Missense; Polycythemia Vera; Primary Myelofibrosis; Prognosis; Protein Kinase Inhibitors; Quinazolines; Thrombocythemia, Essential; Thrombophilia	2009
How to manage essential thrombocythemia. Leukemia, 2012, Volume: 26, Issue:5 Topics: Female; Heparin, Low-Molecular-Weight; Humans; Hydroxyurea; Interferon-alpha; Pregnancy; Pregnancy Complications, Hematologic; Quinazolines; Risk Factors; Thrombocythemia, Essential	2012
Headache in essential thrombocythaemia. International journal of clinical practice, 2012, Volume: 66, Issue:10 Topics: Alkylating Agents; Analgesics; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Headache Disorders; Humans; Hydroxyurea; Immunologic Factors; Interferon-alpha; Phosphorus Radioisotopes; Platelet Aggregation Inhibitors; Quinazolines; Radiopharmaceuticals; Risk Factors; Thrombocythemia, Essential	2012
[Treatment of essential thrombocythemia]. Medicina clinica, 2013, Sep-21, Volume: 141, Issue:6 Topics: Adult; Age Factors; Aged; Anticoagulants; Aspirin; Cell Transformation, Neoplastic; Disease Progression; Female; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Hydroxyurea; Intraoperative Complications; Janus Kinase 2; Leukemia, Myeloid, Acute; Life Expectancy; Male; Middle Aged; Mutation, Missense; Platelet Aggregation Inhibitors; Point Mutation; Pregnancy; Pregnancy Complications, Hematologic; Primary Myelofibrosis; Quinazolines; Risk Factors; Thrombocythemia, Essential; Thrombophilia	2013
Paediatric essential thrombocythaemia: clinical and molecular features, diagnosis and treatment. British journal of haematology, 2013, Volume: 163, Issue:3 Topics: Adolescent; Age of Onset; Anticoagulants; Child; Child, Preschool; Clone Cells; Disease Progression; GPI-Linked Proteins; Hemorrhage; Humans; Hydroxyurea; Incidence; Infant; Isoantigens; Janus Kinase 2; Leukemia, Myeloid, Acute; Platelet Aggregation Inhibitors; Point Mutation; Primary Myelofibrosis; Quinazolines; Receptors, Cell Surface; Risk Assessment; Symptom Assessment; Thrombocythemia, Essential; Thrombophilia	2013
Therapeutic options for patients with polycythemia vera and essential thrombocythemia refractory/resistant to hydroxyurea. Leukemia & lymphoma, 2014, Volume: 55, Issue:12 Topics: Antineoplastic Agents; Busulfan; Disease Management; Drug Resistance; Histone Deacetylase Inhibitors; Humans; Hydroxyurea; Interferon-alpha; Janus Kinase 2; Pipobroman; Platelet Aggregation Inhibitors; Polycythemia Vera; Protein Kinase Inhibitors; Quinazolines; Thrombocythemia, Essential; Treatment Outcome	2014
[Treatment strategy for myeloproliferative neoplasms]. [Rinsho ketsueki] The Japanese journal of clinical hematology, 2014, Volume: 55, Issue:10 Topics: Adrenal Cortex Hormones; Aspirin; Calreticulin; Carbamates; Clinical Trials as Topic; Drug Therapy, Combination; Hematopoietic Stem Cell Transplantation; Humans; Hydroxyurea; Immunosuppressive Agents; Janus Kinase 2; Molecular Targeted Therapy; Mutation; Nitriles; Platelet Aggregation Inhibitors; Polycythemia Vera; Primary Myelofibrosis; Prognosis; Pyrazoles; Pyrimidines; Quinazolines; Receptors, Thrombopoietin; Thalidomide; Thrombocythemia, Essential	2014
Anagrelide hydrochloride and ruxolitinib for treatment of polycythemia vera. Expert opinion on pharmacotherapy, 2015, Volume: 16, Issue:8 Topics: Aspirin; Drug Therapy, Combination; Fibrinolytic Agents; Humans; Hydroxyurea; Interferon-alpha; Nitriles; Platelet Aggregation Inhibitors; Polycythemia Vera; Polyethylene Glycols; Pyrazoles; Pyrimidines; Quinazolines	2015
Anagrelide compared with hydroxyurea in essential thrombocythemia: a meta-analysis. Journal of thrombosis and thrombolysis, 2015, Volume: 40, Issue:4 Topics: Hemorrhage; Humans; Hydroxyurea; Quinazolines; Thrombocythemia, Essential; Thrombosis	2015
Pharmacobiological Approach for the Clinical Development of Ruxolitinib in Myeloproliferative Neoplasms. Turkish journal of haematology : official journal of Turkish Society of Haematology, 2015, Volume: 32, Issue:2 Topics: Bone Marrow; Combined Modality Therapy; Disease Progression; Female; Fibrosis; Humans; Hydroxyurea; Janus Kinase 2; Leukapheresis; Middle Aged; Myeloproliferative Disorders; Nitriles; Phlebotomy; Point Mutation; Polycythemia Vera; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Quinazolines; Splenectomy; Splenomegaly	2015
Essential Thrombocythemia: The Dermatologic Point of View. Clinical lymphoma, myeloma & leukemia, 2015, Volume: 15, Issue:12 Topics: Antineoplastic Agents; Humans; Hydroxyurea; Interferon-alpha; Quinazolines; Skin Diseases; Thrombocythemia, Essential	2015
Thrombocytosis in children and adolescents-classification, diagnostic approach, and clinical management. Annals of hematology, 2021, Volume: 100, Issue:7 Topics: Adolescent; Adult; Age of Onset; Algorithms; Anticoagulants; Calreticulin; Child; Disease Management; Female; Germ-Line Mutation; Humans; Hydroxyurea; Interferon-alpha; Janus Kinase 2; Male; Myelodysplastic-Myeloproliferative Diseases; Platelet Count; Quinazolines; Receptors, Thrombopoietin; Severity of Illness Index; Thrombocythemia, Essential; Thrombocytosis; Thrombophilia	2021
SURPASS-ET: phase III study of ropeginterferon alfa-2b versus anagrelide as second-line therapy in essential thrombocythemia. Future oncology (London, England), 2022, Volume: 18, Issue:27 Topics: Clinical Trials, Phase III as Topic; Humans; Hydroxyurea; Multicenter Studies as Topic; Quinazolines; Randomized Controlled Trials as Topic; Thrombocythemia, Essential	2022

Trials

14 trial(s) available for quinazolines and hydroxyurea

Article	Year
Anagrelide, a therapy for thrombocythemic states: experience in 577 patients. Anagrelide Study Group. The American journal of medicine, 1992, Volume: 92, Issue:1 Topics: Aged; Clinical Protocols; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Hydroxyurea; Male; Middle Aged; Platelet Aggregation Inhibitors; Platelet Count; Quinazolines; Thrombocytosis; Treatment Outcome	1992
Anagrelide is effective in treating patients with hydroxyurea-resistant thrombocytosis in patients with chronic myeloid leukemia. Leukemia, 2005, Volume: 19, Issue:1 Topics: Adult; Drug Resistance; Female; Humans; Hydroxyurea; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Quinazolines; Thrombocytosis	2005
Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. The New England journal of medicine, 2005, Jul-07, Volume: 353, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Aspirin; Drug Therapy, Combination; Female; Follow-Up Studies; Hemorrhage; Humans; Hydroxyurea; Leukemia, Myeloid, Acute; Male; Middle Aged; Platelet Aggregation Inhibitors; Platelet Count; Primary Myelofibrosis; Quinazolines; Thrombocythemia, Essential; Thrombosis	2005
Bone marrow pathology in essential thrombocythemia: interobserver reliability and utility for identifying disease subtypes. Blood, 2008, Jan-01, Volume: 111, Issue:1 Topics: Adult; Antineoplastic Agents; Aspirin; Biopsy; Blood Cell Count; Drug Therapy, Combination; Hematology; Humans; Hydroxyurea; Megakaryocytes; Observer Variation; Pathology, Clinical; Platelet Aggregation Inhibitors; Polycythemia Vera; Primary Myelofibrosis; Prospective Studies; Quinazolines; Thrombocytosis	2008
Effect of anagrelide on platelet coagulant function in patients with essential thrombocythemia. Acta haematologica, 2007, Volume: 118, Issue:4 Topics: Adult; Aged; Antithrombin III; Aspirin; Drug Therapy, Combination; Female; Fibrin Fibrinogen Degradation Products; Hemorrhage; Humans; Hydroxyurea; Male; Middle Aged; Peptide Fragments; Peptide Hydrolases; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Count; Platelet Factor 4; Prothrombin; Quinazolines; Thrombocythemia, Essential; Thrombosis	2007
Reticulin accumulation in essential thrombocythemia: prognostic significance and relationship to therapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Jun-20, Volume: 27, Issue:18 Topics: Biomarkers; Bone Marrow; Hemoglobins; Hemorrhage; Humans; Hydroxyurea; Leukocyte Count; Platelet Aggregation Inhibitors; Platelet Count; Primary Myelofibrosis; Prognosis; Prospective Studies; Quinazolines; Reticulin; Thrombocythemia, Essential; Thrombosis	2009
Efficacy and safety of cytoreductive therapies in patients with essential thrombocythaemia aged >80 years: an interim analysis of the EXELS study. Clinical drug investigation, 2013, Volume: 33, Issue:1 Topics: Age Factors; Aged, 80 and over; Analysis of Variance; Chi-Square Distribution; Drug Substitution; Europe; Female; Hematologic Agents; Humans; Hydroxyurea; Kaplan-Meier Estimate; Male; Platelet Count; Prospective Studies; Quinazolines; Risk Factors; Thrombocythemia, Essential; Time Factors; Treatment Outcome	2013
Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial. Blood, 2013, Mar-07, Volume: 121, Issue:10 Topics: Adult; Aged; Aged, 80 and over; Female; Follow-Up Studies; Humans; Hydroxyurea; Male; Maximum Tolerated Dose; Middle Aged; Nucleic Acid Synthesis Inhibitors; Platelet Aggregation Inhibitors; Prognosis; Prospective Studies; Quinazolines; Retrospective Studies; Single-Blind Method; Thrombocythemia, Essential; World Health Organization; Young Adult	2013
Combination therapy of hydroxycarbamide with anagrelide in patients with essential thrombocythemia in the evaluation of Xagrid(R) efficacy and long-term safety study. Haematologica, 2014, Volume: 99, Issue:4 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Blood Cell Count; Drug Therapy, Combination; Female; Humans; Hydroxyurea; Interferons; Male; Middle Aged; Quinazolines; Thrombocythemia, Essential; Treatment Outcome; Young Adult	2014
[Efficacy and safety of anagrelide in treatment of essential thrombocythemia: multicenter, randomized controlled clinical trial]. Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2015, Volume: 36, Issue:7 Topics: Humans; Hydroxyurea; Platelet Aggregation Inhibitors; Platelet Count; Quinazolines; Thrombocythemia, Essential; Treatment Outcome	2015
Leukemic transformation and second cancers in 3649 patients with high-risk essential thrombocythemia in the EXELS study. Leukemia research, 2018, Volume: 74 Topics: Adult; Aged; Aged, 80 and over; Cell Transformation, Neoplastic; Female; Humans; Hydroxyurea; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasms, Second Primary; Quinazolines; Thrombocythemia, Essential	2018
Long-term efficacy and safety of ruxolitinib versus best available therapy in polycythaemia vera (RESPONSE): 5-year follow up of a phase 3 study. The Lancet. Haematology, 2020, Volume: 7, Issue:3 Topics: Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Drug Therapy, Combination; Fibrinolytic Agents; Follow-Up Studies; Humans; Hydroxyurea; Interferon alpha-2; Interferon-alpha; Nitriles; Pipobroman; Polycythemia Vera; Polyethylene Glycols; Prognosis; Pyrazoles; Pyrimidines; Quinazolines; Recombinant Proteins; Survival Rate; Time Factors	2020
Cytoreductive treatment in patients with CALR-mutated essential thrombocythaemia: a study comparing indications and efficacy among genotypes from the Spanish Registry of Essential Thrombocythaemia. British journal of haematology, 2021, Volume: 192, Issue:6 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amino Acid Substitution; Calreticulin; Child; Female; Follow-Up Studies; Genotype; Humans; Hydroxyurea; Janus Kinase 2; Male; Middle Aged; Mutation, Missense; Quinazolines; Registries; Spain; Thrombocythemia, Essential	2021
Cardiovascular Safety of Anagrelide Hydrochloride versus Hydroxyurea in Essential Thrombocythaemia. Cardiovascular toxicology, 2021, Volume: 21, Issue:3 Topics: Adolescent; Adult; Aged; Biopsy; Blood Platelets; Bone Marrow Examination; Echocardiography; Europe; Female; Humans; Hydroxyurea; Male; Middle Aged; Platelet Count; Quinazolines; Stroke Volume; Thrombocythemia, Essential; Time Factors; Treatment Outcome; Ventricular Dysfunction, Left; Ventricular Function, Left; Young Adult	2021

Other Studies

54 other study(ies) available for quinazolines and hydroxyurea

Article	Year
Anagrelide-induced relapse of a hydroxyurea-induced leg ulcer in a patient with primary thrombocythemia. Mayo Clinic proceedings, 1998, Volume: 73, Issue:11 Topics: Aged; Antineoplastic Agents; Female; Fibrinolytic Agents; Humans; Hydroxyurea; Leg Ulcer; Platelet Aggregation Inhibitors; Quinazolines; Recurrence; Thrombocythemia, Essential	1998
Thrombocytosis--report of a case. The Journal of the Association of Physicians of India, 2000, Volume: 48, Issue:4 Topics: Aged; Antineoplastic Agents; Female; Humans; Hydroxyurea; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Platelet Aggregation Inhibitors; Platelet Count; Quinazolines; Thrombocytosis	2000
Hydroxyurea and periodicity in myeloproliferative disease. European journal of haematology, 2001, Volume: 66, Issue:5 Topics: Adult; Aged; Antineoplastic Agents; Blood Cell Count; Busulfan; Female; Hemoglobins; Humans; Hydroxyurea; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocyte Count; Lymphocytes; Male; Monocytes; Neutrophils; Periodicity; Platelet Count; Polycythemia Vera; Quinazolines	2001
[How should patients with essential thrombocythemia be treated?]. [Rinsho ketsueki] The Japanese journal of clinical hematology, 2001, Volume: 42, Issue:6 Topics: Clinical Trials as Topic; Enzyme Inhibitors; Humans; Hydroxyurea; Leukemia; Platelet Aggregation Inhibitors; Quinazolines; Thrombocythemia, Essential	2001
Chronic myeloid leukaemia with marked thrombocytosis in a patient with thalassaemia major: complete haematological remission under the combination of hydroxyurea and anagrelide. British journal of haematology, 2002, Volume: 116, Issue:1 Topics: Adult; Antisickling Agents; beta-Thalassemia; Drug Therapy, Combination; Humans; Hydroxyurea; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocyte Count; Male; Platelet Aggregation Inhibitors; Platelet Count; Quinazolines; Remission Induction; Thrombocytosis	2002
Cost-effectiveness considerations in the treatment of essential thrombocythemia. Seminars in oncology, 2002, Volume: 29, Issue:3 Suppl 10 Topics: Antineoplastic Agents; Cost-Benefit Analysis; Fibrinolytic Agents; Humans; Hydroxyurea; Immunologic Factors; Interferon-alpha; Nucleic Acid Synthesis Inhibitors; Quinazolines; Thrombocytosis	2002
Efficacy and safety of long-term use of hydroxyurea in young patients with essential thrombocythemia and a high risk of thrombosis. Blood, 2003, May-01, Volume: 101, Issue:9 Topics: Adolescent; Adult; Anemia; Cohort Studies; Follow-Up Studies; Hemorrhage; Humans; Hydroxyurea; Incidence; Middle Aged; Quinazolines; Risk; Thrombocythemia, Essential; Thrombophilia; Thrombosis	2003
Severe hypersensitivity pneumonitis associated with anagrelide. The Annals of pharmacotherapy, 2003, Volume: 37, Issue:9 Topics: Adrenal Cortex Hormones; Alveolitis, Extrinsic Allergic; Antineoplastic Agents; Drug Interactions; Female; Humans; Hydroxyurea; Injections, Intravenous; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Platelet Aggregation Inhibitors; Quinazolines; Thrombocytosis	2003
Associated thrombophilic defects in essential thrombocythaemia: their relationship with clinical manifestations. Thrombosis research, 2003, Volume: 112, Issue:3 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amino Acid Substitution; Antithrombin III; Child; Female; Humans; Hydroxyurea; Male; Middle Aged; Platelet Aggregation Inhibitors; Protein C; Prothrombin; Quinazolines; Reference Values; Thrombocythemia, Essential; Thrombophilia	2003
Thrombocytosis. The New England journal of medicine, 2004, Jun-10, Volume: 350, Issue:24 Topics: Humans; Hydroxyurea; Platelet Aggregation Inhibitors; Quinazolines; Thrombocytosis	2004
When and how to treat essential thrombocythemia. The New England journal of medicine, 2005, Jul-07, Volume: 353, Issue:1 Topics: Antineoplastic Agents; Aspirin; Drug Therapy, Combination; Hemorrhage; Humans; Hydroxyurea; Leukemia, Myeloid, Acute; Platelet Aggregation Inhibitors; Primary Myelofibrosis; Quinazolines; Risk Factors; Thrombocythemia, Essential; Thrombosis	2005
Anagrelide does not exert a myelodysplastic effect on megakaryopoiesis: a comparative immunohistochemical and morphometric study with hydroxyurea. Histology and histopathology, 2005, Volume: 20, Issue:4 Topics: Antineoplastic Agents; Bone Marrow; Bone Marrow Cells; Humans; Hydroxyurea; Immunohistochemistry; Megakaryocytes; Myelodysplastic Syndromes; Quinazolines; Retrospective Studies; Thrombopoiesis	2005
New approaches to the treatment of thrombocytosis. Clinical advances in hematology & oncology : H&O, 2003, Volume: 1, Issue:2 Topics: Humans; Hydroxyurea; Interferon-alpha; Myeloproliferative Disorders; Platelet Count; Quinazolines; Thrombocytosis	2003
Comparison between anagrelide and hydroxycarbamide in their activities against haematopoietic progenitor cell growth and differentiation: selectivity of anagrelide for the megakaryocytic lineage. Leukemia, 2006, Volume: 20, Issue:6 Topics: Antigens, CD34; Antineoplastic Agents; Apoptosis; Cell Count; Cell Differentiation; Cell Lineage; Cell Proliferation; Cells, Cultured; Dose-Response Relationship, Drug; Hematopoietic Stem Cells; Humans; Hydroxyurea; Megakaryocytes; Quinazolines	2006
Emergence of chronic myelogenous leukemia in a patient with primary thrombocythemia and absence of BCR/ABL rearrangement. Cancer genetics and cytogenetics, 2006, Volume: 167, Issue:1 Topics: Aged; Antineoplastic Agents; Benzamides; Blood Platelets; Bone Marrow Cells; Cells, Cultured; Chromosomes, Human, Pair 22; Chromosomes, Human, Pair 9; Chronic Disease; Dose-Response Relationship, Drug; Female; Fibrinolytic Agents; Fusion Proteins, bcr-abl; Humans; Hydroxyurea; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocytes; Piperazines; Pyrimidines; Quinazolines; Thrombocythemia, Essential; Time Factors; Translocation, Genetic; Treatment Outcome	2006
Anagrelide: new drug. Essential thrombocythaemia: further evaluation needed for this last-resort treatment. Prescrire international, 2006, Volume: 15, Issue:83 Topics: Clinical Trials as Topic; Cost-Benefit Analysis; Drug Approval; Drugs, Investigational; Europe; Humans; Hydroxyurea; Platelet Aggregation Inhibitors; Quinazolines; Thrombocythemia, Essential; Treatment Outcome; Vasodilator Agents	2006
Effects of anagrelide on megakaryopoiesis and platelet production. Seminars in thrombosis and hemostasis, 2006, Volume: 32, Issue:4 Pt 2 Topics: Animals; Antineoplastic Agents; Apoptosis; Bone Marrow; Cell Differentiation; Drug Evaluation; Humans; Hydroxyurea; Megakaryocytes; Mutagenesis; Platelet Aggregation Inhibitors; Ploidies; Primary Myelofibrosis; Quinazolines; Thrombocythemia, Essential; Thrombopoiesis; World Health Organization	2006
Acute biphenotypic leukemia arising in a patient with essential thrombocythemia. American journal of hematology, 2006, Volume: 81, Issue:8 Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Chromosomes, Human, Pair 20; Cytogenetic Analysis; Female; Follow-Up Studies; Humans; Hydroxyurea; Leukemia; Middle Aged; Quinazolines; Remission Induction; Thrombocythemia, Essential; Treatment Outcome	2006
Coronary artery intervention after cytostatics treatment in unstable angina patient with essential thrombocythemia. A case report and literature review. The Korean journal of internal medicine, 2006, Volume: 21, Issue:2 Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Humans; Hydroxyurea; Male; Middle Aged; Quinazolines; Stents; Thrombocythemia, Essential	2006
[Appearance of leg ulcers associated with intake of anagrelide]. Deutsche medizinische Wochenschrift (1946), 2007, Feb-16, Volume: 132, Issue:7 Topics: Adult; Fibrinolytic Agents; Humans; Hydroxyurea; Leg Ulcer; Male; Quinazolines; Thrombocytosis	2007
Essential thrombocythaemia treatment options: addressing patient-specific needs. European journal of haematology. Supplementum, 2007, Issue:68 Topics: Disease Management; Health Services Needs and Demand; Humans; Hydroxyurea; Interferon alpha-2; Interferon-alpha; Platelet Count; Polyethylene Glycols; Quinazolines; Recombinant Proteins; Risk Factors; Thrombocythemia, Essential	2007
Options in the management of essential thrombocythaemia. European journal of haematology. Supplementum, 2007, Issue:68 Topics: Age Factors; Disease Management; Humans; Hydroxyurea; Interferons; Platelet Count; Quinazolines; Risk Factors; Thrombocythemia, Essential	2007
Practical approach to treating essential thrombocythaemia: case studies. European journal of haematology. Supplementum, 2007, Issue:68 Topics: Adult; Aspirin; Disease Management; Female; Humans; Hydroxyurea; Interferon-alpha; Leg Ulcer; Male; Middle Aged; Pipobroman; Platelet Count; Pregnancy; Pregnancy Complications, Hematologic; Quinazolines; Thrombocythemia, Essential; Warfarin	2007
The combined use of hydroxyurea and anagrelide allows satisfactory hematologic control in patients with chronic myeloproliferative disorders and thrombocytosis: a report on 13 patients with poor tolerance to hydroxyurea monotherapy. Leukemia & lymphoma, 2008, Volume: 49, Issue:11 Topics: Adult; Aged; Blood Platelets; Chronic Disease; Drug Therapy, Combination; Drug Tolerance; Female; Hemoglobins; Humans; Hydroxyurea; Male; Middle Aged; Myeloproliferative Disorders; Quinazolines; Retrospective Studies; Thrombocytosis	2008
Hydroxyurea and anagrelide combination therapy in patients with chronic myeloproliferative diseases resistant or intolerant to monotherapy. Acta haematologica, 2008, Volume: 120, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Drug Resistance; Drug Therapy, Combination; Female; Humans; Hydroxyurea; Male; Middle Aged; Polycythemia Vera; Quinazolines; Thrombocythemia, Essential	2008
Limited efficacy of hydroxyurea in lowering of the JAK2 V617F allele burden. Hematology (Amsterdam, Netherlands), 2009, Volume: 14, Issue:1 Topics: Alleles; Chronic Disease; Female; Humans; Hydroxyurea; Janus Kinase 2; Male; Mutation; Myeloproliferative Disorders; Platelet Aggregation Inhibitors; Polymerase Chain Reaction; Prospective Studies; Quinazolines	2009
Management of refractory essential thrombocythemia with anagrelide in a patient undergoing hemodialysis. Clinical therapeutics, 2009, Volume: 31, Issue:11 Topics: Aged; Aspirin; Blood Cell Count; Blood Chemical Analysis; Blood Transfusion; Drug Resistance; Erythropoietin; Fatal Outcome; Female; Humans; Hydroxyurea; Jehovah's Witnesses; Kidney Failure, Chronic; Kidney Function Tests; Platelet Aggregation Inhibitors; Platelet Count; Quinazolines; Recombinant Proteins; Renal Dialysis; Thrombocythemia, Essential	2009
Melanonychia secondary to hydroxyurea. Internal and emergency medicine, 2012, Volume: 7, Issue:3 Topics: Aged; Enzyme Inhibitors; Female; Humans; Hydroxyurea; Hyperpigmentation; Nail Diseases; Platelet Aggregation Inhibitors; Plateletpheresis; Quinazolines; Risk Factors	2012
Impaired apoptosis of megakaryocytes and bone marrow mononuclear cells in essential thrombocythemia: correlation with JAK2V617F mutational status and cytoreductive therapy. Medical oncology (Northwood, London, England), 2012, Volume: 29, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Apoptosis; Bone Marrow Cells; Female; Humans; Hydroxyurea; Janus Kinase 2; Male; Megakaryocytes; Middle Aged; Mutation; Proto-Oncogene Proteins c-bcl-2; Quinazolines; Thrombocythemia, Essential	2012
Clinical evaluation of the European LeukemiaNet response criteria in patients with essential thrombocythemia treated with anagrelide. Annals of hematology, 2013, Volume: 92, Issue:6 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Biomarkers; Disease-Free Survival; Female; Follow-Up Studies; Humans; Hydroxyurea; Interferons; International Agencies; Kaplan-Meier Estimate; Leukocyte Count; Male; Middle Aged; Organ Size; Platelet Aggregation Inhibitors; Platelet Count; Prognosis; Quinazolines; Remission Induction; Retrospective Studies; Spain; Spleen; Survival Analysis; Thrombocythemia, Essential; Treatment Outcome; Young Adult	2013
The therapeutic goals of essential thrombocythemia under the clouds of over-treatment and under-treatment. Expert opinion on pharmacotherapy, 2013, Volume: 14, Issue:11 Topics: Aspirin; Fibrinolytic Agents; Humans; Hydroxyurea; Interferon-alpha; Platelet Aggregation Inhibitors; Quinazolines; Risk Assessment; Thrombocythemia, Essential	2013
Successful long-term treatment of Philadelphia chromosome-negative myeloproliferative neoplasms with combination of hydroxyurea and anagrelide. Clinical lymphoma, myeloma & leukemia, 2013, Volume: 13 Suppl 2 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Hydroxyurea; Male; Middle Aged; Myeloproliferative Disorders; Philadelphia Chromosome; Polycythemia Vera; Quinazolines; Retrospective Studies; Thrombocythemia, Essential; Thrombosis	2013
Successful management of acute bleeding in essential thrombocythemia using automated cell separator. Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis, 2014, Volume: 50, Issue:1 Topics: Administration, Oral; Adolescent; Automation; Blood Platelets; Body Weight; Cell Separation; Female; Hemorrhage; Humans; Hydroxyurea; Platelet Count; Quinazolines; Thrombocythemia, Essential; Thrombocytosis	2014
Dermatomyositis-like eruption associated with hydroxyurea therapy: a premalignant condition? Actas dermo-sifiliograficas, 2014, Volume: 105, Issue:9 Topics: Aged; Dermatomyositis; Diagnosis, Differential; Drug Eruptions; Drug Substitution; Erythema; Female; Humans; Hydroxyurea; Leg Ulcer; Lichenoid Eruptions; Precancerous Conditions; Primary Myelofibrosis; Quinazolines	2014
Re-evaluation of cytostatic therapies for meningiomas in vitro. Journal of cancer research and clinical oncology, 2014, Volume: 140, Issue:8 Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Dacarbazine; DNA Methylation; DNA Modification Methylases; DNA Repair Enzymes; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Erlotinib Hydrochloride; Humans; Hydroxyurea; Losartan; Meningeal Neoplasms; Meningioma; Metformin; Mifepristone; Neurofibromin 2; Promoter Regions, Genetic; Quinazolines; Radiation Tolerance; Tamoxifen; Temozolomide; Tumor Suppressor Proteins; Verapamil	2014
Essential differences in clinical and bone marrow features in BCR/ABL-positive thrombocythemia compared to thrombocythemia in the BCR/ABL-negative myeloproliferative neoplasms essential thrombocythemia and polycythemia vera. Acta haematologica, 2015, Volume: 133, Issue:1 Topics: Aged; Alleles; Benzamides; Biopsy; Bone Marrow; Diagnosis, Differential; Drug Therapy, Combination; Female; Fusion Proteins, bcr-abl; Humans; Hydroxyurea; Imatinib Mesylate; Janus Kinase 2; Male; Middle Aged; Mutation; Myeloproliferative Disorders; Piperazines; Platelet Count; Polycythemia Vera; Pyrimidines; Quinazolines; Thrombocythemia, Essential; Treatment Outcome	2015
Prophylaxis and management of venous thromboembolism in patients with myeloproliferative neoplasms: consensus statement of the Haemostasis Working Party of the German Society of Hematology and Oncology (DGHO), the Austrian Society of Hematology and Oncolo Annals of hematology, 2014, Volume: 93, Issue:12 Topics: Anticoagulants; Disease Susceptibility; Drug Interactions; Female; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Hydroxyurea; Incidence; Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative; Male; Myeloproliferative Disorders; Phlebotomy; Platelet Aggregation Inhibitors; Postoperative Complications; Pregnancy; Pregnancy Complications, Hematologic; Preoperative Care; Protein Kinase Inhibitors; Quinazolines; Secondary Prevention; Thrombophilia; Venous Thromboembolism; von Willebrand Diseases	2014
Essential thrombocythaemia. Hematology (Amsterdam, Netherlands), 2015, Volume: 20, Issue:2 Topics: Age Factors; Antineoplastic Agents; Blood Platelets; Calreticulin; Gene Expression; Humans; Hydroxyurea; Immunologic Factors; Interferon-alpha; Janus Kinase 2; Mutation; Platelet Aggregation Inhibitors; Quinazolines; Receptors, Thrombopoietin; Risk Factors; Thrombocythemia, Essential	2015
Prediction of thrombotic and hemorrhagic events during polycythemia vera or essential thrombocythemia based on leukocyte burden. Thrombosis research, 2015, Volume: 135, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Area Under Curve; Blood Cell Count; Comorbidity; Databases, Factual; Female; Follow-Up Studies; Hemorrhage; Hemorrhagic Disorders; Humans; Hydroxyurea; Leukocyte Count; Male; Middle Aged; Phlebotomy; Platelet Aggregation Inhibitors; Polycythemia Vera; Prognosis; Quinazolines; Retrospective Studies; Risk Factors; Thrombocythemia, Essential; Thrombophilia; Thrombosis; Young Adult	2015
[Treatment outcome of patients with essential thrombocythemia at our department in Hungary]. Orvosi hetilap, 2016, Feb-28, Volume: 157, Issue:9 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Hungary; Hydroxyurea; Interferons; Male; Middle Aged; Platelet Aggregation Inhibitors; Quinazolines; Survival Analysis; Thrombocythemia, Essential; Treatment Failure; Treatment Outcome	2016
Current opinion and consensus statement regarding the diagnosis, prognosis, and treatment of patients with essential thrombocythemia: a survey of the Spanish Group of Ph-negative Myeloproliferative Neoplasms (GEMFIN) using the Delphi method. Annals of hematology, 2016, Volume: 95, Issue:5 Topics: Bone Marrow Examination; Delphi Technique; Diagnosis, Differential; Disease Management; DNA Mutational Analysis; Humans; Hydroxyurea; Janus Kinase 2; Mutation, Missense; Platelet Count; Polycythemia Vera; Prognosis; Quinazolines; Receptors, Thrombopoietin; Risk Assessment; Surveys and Questionnaires; Thrombocythemia, Essential; Thrombophilia	2016
Clinical Features of 294 Turkish Patients with Chronic Myeloproliferative Neoplasms. Turkish journal of haematology : official journal of Turkish Society of Haematology, 2016, Sep-05, Volume: 33, Issue:3 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Chronic Disease; Female; Hemorrhage; Humans; Hydroxyurea; Janus Kinase 2; Male; Middle Aged; Mutation; Myeloproliferative Disorders; Quinazolines; Retrospective Studies; Risk Factors; Turkey; Venous Thromboembolism; Young Adult	2016
Acute pancreatitis as a side effect of anagrelide hydrochloride hydrate: a case report. Annals of hematology, 2016, Volume: 95, Issue:11 Topics: Abdominal Pain; Acute Disease; Aged; Aspirin; Drug Substitution; Female; Humans; Hydroxyurea; Janus Kinase 2; Mutation; Pancreatitis; Phosphodiesterase Inhibitors; Quinazolines; Thrombocythemia, Essential	2016
Anagrelide reduces thrombotic risk in essential thrombocythaemia vs. hydroxyurea plus aspirin. European journal of haematology, 2017, Volume: 98, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Aspirin; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Hungary; Hydroxyurea; Male; Middle Aged; Platelet Aggregation Inhibitors; Quinazolines; Risk; Thrombocythemia, Essential; Thrombosis	2017
Observational retrospective study of vascular modulator changes during treatment in essential thrombocythemia. Translational research : the journal of laboratory and clinical medicine, 2017, Volume: 184 Topics: Adrenomedullin; Aged; Aspirin; Blood Platelets; Case-Control Studies; Cell-Derived Microparticles; Endothelin-1; Endothelium, Vascular; Female; Humans; Hydroxyurea; Male; Middle Aged; Nitric Oxide; Quinazolines; Retrospective Studies; Thrombocythemia, Essential	2017
Hemorrhage and Infarction of the Conjunctiva and Orbit in Essential Thrombocythemia. The Journal of craniofacial surgery, 2017, Volume: 28, Issue:3 Topics: Aged, 80 and over; Biopsy; Conjunctiva; Eye Hemorrhage; Female; Hematologic Agents; Humans; Hydroxyurea; Orbit; Quinazolines; Thrombocythemia, Essential; Thrombosis; Tomography, X-Ray Computed; Treatment Outcome; Visual Acuity	2017
Role of treatment on the development of secondary malignancies in patients with essential thrombocythemia. Cancer medicine, 2017, Volume: 6, Issue:6 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Alkylating Agents; Antineoplastic Combined Chemotherapy Protocols; Female; Fibrinolytic Agents; Humans; Hydroxyurea; Interferon-alpha; Male; Middle Aged; Neoplasms, Second Primary; Quinazolines; Thrombocythemia, Essential; Young Adult	2017
JSH guideline for tumors of hematopoietic and lymphoid tissues-lukemia: 4. Chronic myelogenous leukemia (CML)/myeloproliferative neoplasms (MPN). International journal of hematology, 2017, Volume: 106, Issue:5 Topics: Algorithms; Aniline Compounds; Antineoplastic Agents; Aspirin; Blood Transfusion; Dasatinib; Hematopoietic Stem Cell Transplantation; Humans; Hydroxyurea; Imidazoles; Japan; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Myeloproliferative Disorders; Nitriles; Phlebotomy; Prognosis; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Pyridazines; Pyrimidines; Quinazolines; Quinolines; Risk	2017
Ventricular tachyarrhythmia in a 78-year-old woman with essential thrombocythaemia. BMJ case reports, 2018, Feb-08, Volume: 2018 Topics: Age Factors; Aged; Electrocardiography; Female; Humans; Hydroxyurea; Platelet Aggregation Inhibitors; Quinazolines; Risk Factors; Tachycardia, Ventricular; Thrombocythemia, Essential	2018
Successful replantation of 2 digits in a patient with thrombocytosis after splenectomy: A case report. Medicine, 2018, Volume: 97, Issue:22 Topics: Adolescent; Amputation, Traumatic; Finger Injuries; Fingers; Humans; Hydroxyurea; Male; Platelet Count; Quinazolines; Replantation; Splenectomy; Splenic Rupture; Thrombocytosis	2018
Clinical Evaluation of the Efficacy and Safety of Anagrelide Used with or without Hydroxycarbamide in Japanese Patients with Essential Thrombocythemia-A Retrospective Single-Center Study of 35 Cases. Gan to kagaku ryoho. Cancer & chemotherapy, 2019, Volume: 46, Issue:7 Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Hydroxyurea; Japan; Quinazolines; Retrospective Studies; Thrombocythemia, Essential	2019
Anagrelide influences thrombotic risk, and prolongs progression-free and overall survival in essential thrombocythaemia vs hydroxyurea plus aspirin. European journal of haematology, 2020, Volume: 105, Issue:4 Topics: Aspirin; Drug Therapy, Combination; Health Care Surveys; Humans; Hungary; Hydroxyurea; Quinazolines; Registries; Thrombocythemia, Essential; Thrombosis; Treatment Outcome	2020
Treatment of Essential Thrombocythemia with Anagrelide Is Associated with an Increased Risk of Worsened Kidney Function. Pharmacology, 2021, Volume: 106, Issue:5-6 Topics: Aged; Calreticulin; Creatinine; Disease Progression; Female; Humans; Hydroxyurea; Janus Kinase 2; Kidney Diseases; Male; Middle Aged; Mutation; Platelet Aggregation Inhibitors; Quinazolines; Retrospective Studies; Risk Factors; Thrombocythemia, Essential; Treatment Outcome	2021
Modifying the Effects of Cytoreductive Drugs on Kidney Function in Myeloproliferative Neoplasms. Pharmacology, 2021, Volume: 106, Issue:7-8 Topics: Humans; Hydroxyurea; Kidney Function Tests; Myeloproliferative Disorders; Platelet Aggregation Inhibitors; Quinazolines; Thrombocythemia, Essential	2021